Niraparib-pembrolizumab combo finds niche in breast, ovarian cancersJune 17, 2019Gynecologic CancerBreast CancerImmuno-oncology
FDA approves trastuzumab-anns for HER2-positive breast, gastric cancerJune 14, 2019Breast CancerGastroenterologyGastrointestinal Cancer
PREDIX HER2 trial: Similar efficacy, less toxicity with T-DM1 for HER2+, HR+ breast cancerJune 12, 2019Breast Cancer
KRISTINE: Three-year data help forge path to T-DM1-based deescalation in HER2+ BCJune 12, 2019Breast Cancer
Pregnancy deemed safe in BRCA-mutated breast cancer survivorsJune 11, 2019Breast CancerPatient & Survivor Care
ASCO clinical practice guideline update incorporates Oncotype DXJune 4, 2019Breast CancerPatient & Survivor Care
Ribociclib/ET improves OS in premenopausal women with HR+/HER2- breast cancerJune 2, 2019Breast Cancer
Ribociclib plus endocrine therapy boosts survival of HR+/HER2- breast cancerJune 1, 2019Breast Cancer
Use of Oncotype DX to tailor breast cancer treatment likely to reduce costsMay 19, 2019Breast CancerPractice Management
Diet linked to lower risk of death from breast cancerMay 16, 2019Breast CancerPatient & Survivor Care
